Predictive factors for the efficacy of abiraterone acetate therapy in high-risk metastatic hormone-sensitive prostate cancer patients-Reference-Cited by-同舟云学术

Predictive factors for the efficacy of abiraterone acetate therapy in high-risk metastatic hormone-sensitive prostate cancer patients

Published:2022-11-04 Issue:12 Volume:40 Page:2939-2946
ISSN:1433-8726
Container-title:World Journal of Urology
language:en
Short-container-title:World J Urol

Author:

Ueda Takashi^ORCID,Fujita Kazutoshi,Nishimoto Mitsuhisa,Shiraishi Takumi,Miyashita Masatsugu,Kayukawa Naruhiro,Nakamura Yuichi,Sako Satoshi,Ogura Ryota,Fujihara Atsuko,Minami Takafumi,Hongo Fumiya,Okihara Koji,Yoshimura Kazuhiro,Uemura Hirotsugu,Ukimura Osamu

Publisher

Springer Science and Business Media LLC

Subject

Urology

Link

https://link.springer.com/content/pdf/10.1007/s00345-022-04200-2.pdf

Reference23 articles.

1. Claessens F, Verrijdt G, Schoenmakers E et al (2001) Selective DNA binding by the androgen receptor as a mechanism for hormone-specific gene regulation. J Steroid Biochem Mol Biol 76:23–30. https://doi.org/10.1016/s0960-0760(00)00154-0

2. Ito S, Ueno A, Ueda T et al (2018) CNPY2 inhibits MYLIP-mediated AR protein degradation in prostate cancer cells. Oncotarget 9:17645–17655. https://doi.org/10.18632/oncotarget.24824

3. Crawford ED, Schellhammer PF, McLeod DG et al (2018) Androgen receptor targeted treatments of prostate cancer: 35 years of progress with antiandrogens. J Urol 200:956–966. https://doi.org/10.1016/j.juro.2018.04.083

4. Fizazi K, Tran N, Fein L et al (2019) Abiraterone acetate plus prednisone in patients with newly diagnosed high-risk metastatic castration-sensitive prostate cancer (LATITUDE): final overall survival analysis of a randomised, double-blind, phase 3 trial. Lancet Oncol 20:686–700. https://doi.org/10.1016/S1470-2045(19)30082-8

5. Chi KN, Agarwal N, Bjartell A et al (2019) Apalutamide for metastatic, castration-sensitive prostate cancer. N Engl J Med 381:13–24. https://doi.org/10.1056/NEJMoa1903307

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Clinical Outcomes and Risk Stratification in Patients With Metastatic Hormone-Sensitive Prostate Cancer Treated With New-Generation Androgen Receptor Signaling Inhibitors;Clinical Genitourinary Cancer;2024-10

2. Clinical efficacy of different androgen deprivation therapies for prostate cancer and evaluation based on dynamic-contrast enhanced magnetic resonance imaging;Acta Biochimica Polonica;2024-05-15

3. Comparative effectiveness of multiple androgen receptor signaling inhibitor medicines with androgen deprivation therapy for metastatic hormone-sensitive prostate cancer: a study in the real world;Frontiers in Oncology;2024-04-18

4. Apalutamide versus bicalutamide in combination with androgen deprivation therapy for metastatic hormone sensitive prostate cancer;Scientific Reports;2024-01-06